IL7R and acute lymphoblastic leukemia: Overall, these findings indicate that biopharmaceuticals targeting the IL-7/IL-7Rα axis may benefit a large fraction of T-ALL patients (70–80% of the cases), including those with ultra-high risk relapsed disease.